Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H32ClFO5 |
| Molecular Weight | 478.981 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC(=O)O[C@@]1([C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)C(=O)C[C@]12C)C(=O)CCl
InChI
InChIKey=FBRAWBYQGRLCEK-AVVSTMBFSA-N
InChI=1S/C26H32ClFO5/c1-5-6-22(32)33-26(21(31)14-27)15(2)11-19-18-8-7-16-12-17(29)9-10-23(16,3)25(18,28)20(30)13-24(19,26)4/h9-10,12,15,18-19H,5-8,11,13-14H2,1-4H3/t15-,18-,19-,23-,24-,25-,26-/m0/s1
| Molecular Formula | C26H32ClFO5 |
| Molecular Weight | 478.981 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.medicines.org.uk/emc/medicine/2607Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/12775314 and http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con239418.pdf
Sources: https://www.medicines.org.uk/emc/medicine/2607
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/12775314 and http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con239418.pdf
Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis. It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline. Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal.
Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Clobetasone butyrate relieves the symptoms of a flare-up by reducing inflammation, itching and redness. It is not a cure for the condition, but it will help to relieve the symptoms. Although less potent topical steriods are often preferred for use in children, a short course of clobetasone butyrate may be prescribed for a child with severe eczema on the arms or legs. Short courses of clobetasone butyrate may also be prescribed for the treatment of psoriasis for areas such as the face, or the inside of elbows and behind the knees. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.
Originator
Sources: http://www.nps.org.au/medicines/skin/corticosteroids-for-the-skin-topical/clobetasone-butyrate/eumovate-cream
Curator's Comment: https://en.wikipedia.org/wiki/Clobetasone
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2034 Sources: http://www.ncbi.nlm.nih.gov/pubmed/25965047 |
0.19 nM [EC50] | ||
Target ID: CHEMBL364 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18579783 |
6080.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | EUMOVATE CREAM Approved UseEumovate Cream is a moderately potent topical corticosteroid indicated for adults, elderly, children and infants for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.
These include the following:
- Atopic dermatitis
- Irritant or allergic contact dermatitis
- Seborrhoeic dermatitis
- Photodermatitis
- Otitis externa
- Prurigo nodularis
- Insect bite reactions Launch Date1976 |
|||
| Palliative | EUMOVATE CREAM Approved UseEUMOVATE is used to treat eczema and dermatitis Launch Date1976 |
|||
| Palliative | EUMOVATE CREAM Approved UseEUMOVATE is suitable for treating atopic eczema, photodermatitis, otitis externa,
primary irritant and allergic dermatitis, prurigo nodularis, seborrhoeic dermatitis, and
other steroid responsive skin conditions which do not require the use of a more active
topical corticosteroid in children and adults. Launch Date1976 |
|||
| Palliative | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.5 % 2 times / day multiple, topical Highest studied dose Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
|
0.05 % single, topical Recommended Dose: 0.05 % Route: topical Route: single Dose: 0.05 % Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Contact dermatitis... |
0.05 % multiple, topical Recommended Dose: 0.05 % Route: topical Route: multiple Dose: 0.05 % Sources: |
unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Cushings syndrome... AEs leading to discontinuation/dose reduction: Cushings syndrome Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Contact dermatitis | 0.05 % single, topical Recommended Dose: 0.05 % Route: topical Route: single Dose: 0.05 % Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
| Cushings syndrome | Disc. AE | 0.05 % multiple, topical Recommended Dose: 0.05 % Route: topical Route: multiple Dose: 0.05 % Sources: |
unhealthy, CHILD Health Status: unhealthy Age Group: CHILD Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. | 2009-12-17 |
|
| Nocardia keratitis: a case report. | 2006-02-24 |
|
| Use of nonprescription topical steroids: patients' experiences. | 2005-06 |
|
| Acrokeratoelastoidosis. | 2005-05 |
|
| Highly potent and moderately potent topical steroids are effective in treating phimosis: a prospective randomized study. | 2005-04 |
|
| Serum leptin level in children with atopic dermatitis-treated topical steroids. | 2004-06 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/uk/pdf/leaflet/720431.pdf
Eumovate (clobetasone butyrate 0.05%) should be applied thinly and evenly to the affected area(s) of skin up to 2 times a day
Route of Administration:
Topical
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/81679
Clobetasone butyrate depressed proliferation of cell strains derived from normal human foreskin at 10 ug/ml
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:17:38 GMT 2025
by
admin
on
Mon Mar 31 18:17:38 GMT 2025
|
| Record UNII |
8U0H6XI6EO
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
71386
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
8U0H6XI6EO
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
m3629
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
C010893
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
Clobetasone butyrate
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
SUB01347MIG
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
C77409
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
DBSALT001967
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
246-635-9
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
25122-57-0
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
21246
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | RxNorm | ||
|
CHEMBL2308885
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
100000092781
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
DTXSID3046823
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY | |||
|
3911
Created by
admin on Mon Mar 31 18:17:38 GMT 2025 , Edited by admin on Mon Mar 31 18:17:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |